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Abstract
Objective To determine the incremental costs and effects
of different HPV testing strategies, when compared to
Papanicolau cytology (Pap), for cervical cancer screening
in Mexico.
Methods A cost-effectiveness analysis (CEA) examined
the speciﬁc costs and health outcomes associated with (1)
no screening; (2) only the Pap test; (3) only self-adminis-
tered HPV; (4) only clinician administered HPV; and (5)
clinician administered HPV plus the Pap test. The costs of
self- and clinician-HPV testing, as well as with the Pap test,
were identiﬁed and quantiﬁed. Costs were reported in 2008
US dollars. The health outcome associated with these
screening strategies was deﬁned as the number of high-
grade cervical intraepithelial neoplasia or cervical cancer
cases detected. This CEA was performed using the
perspective of the Mexican Institute of Social Security
(IMSS) in Morelos, Mexico.
Results Screening women between the ages of 30–80 for
cervical cancer using clinical-HPV testing or the combi-
nation of clinical-HPV testing, and the Pap is always more
cost-effective than using the Pap test alone.
Conclusions This CEA indicates that HPV testing could
be a cost-effective screening alternative for a large health
delivery organization such as IMSS. These results may
help policy-makers implement HPV testing as part of the
IMSS cervical cancer screening program.
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Although there has been a national cervical cancer
screening program in Mexico since 1974 [1], and despite
technological and scientiﬁc advances, this disease is the
second leading cause of death due to cancer for Mexican
women [2]. A recent study that evaluated the effect of the
national cervical cancer screening program in Mexico
reports that there has been a modest but signiﬁcant
decrease in mortality due to this cancer [3]. Although one
of the main determinants of this decrease is an increase in
early detection through the Pap smear, the authors report
that the persistent low rates of high-grade cervical lesions
detected are due to the poor quality that exists in the Pap
smear collection process and especially in cytologic diag-
nosis. One of the recommendations of this study is to
integrate diverse screening strategies, such as combining
the Pap smear with human papillomavirus (HPV) testing to
the cervical cancer screening program of Mexico[3].
The ofﬁcial recognition of HPV infection as a necessary
cause of cervical cancer [4] has generated an interest in the
use of HPV testing for screening and prevention efforts [5].
In order to evaluate the potential role of HPV testing in
cervical cancer screening, it is important to consider the
beneﬁts and costs associated with this alternative technol-
ogy and compare them to the beneﬁts and costs associated
with Papanicolau (Pap) cytology. The Pap test is currently
the main cervical cancer–screening tool used around the
world, and in some countries, it has signiﬁcantly reduced
the disease burden from cervical cancer [6, 7]. Research
efforts have documented that a well-organized cervical
cancer screening program can potentially reduce cervical
cancer by 60–90% in the 3 years after screening [8, 9].
However, studies have also shown that there are multiple
factors that contribute to the ineffectiveness of many cer-
vical cancer screening programs, including the high false
negative rates of the Pap test, which may result in a mis-
diagnosis or delayed diagnosis. Other factors include poor
quality of care, lack of access to screening and medical
services, and poor follow-up for women with abnormal
results [10, 11]. Several studies have reported a Pap test
sensitivity that ranges from 40–80% for high-grade cervi-
cal intraepithelial neoplasia (CIN) 2/3 [12–14]. The low
sensitivity of the Pap results in a reported false negative
rate of 25 to 50% [15]. The less-than-optimal performance
of the conventional Pap test has helped generate the
development of alternative screening technologies such as
liquid-based cytology, the automated re-screening of
smears, HPV testing, and visual inspection.
Two relatively recent meta-analyses, which report the
ﬁndings of several published studies, indicate that HPV
DNA testing has a greater sensitivity than the Pap test, for
detecting high-grade CIN [16, 17]. These meta-analyses
both indicate that primary screening with the Hybrid
Capture 2 (HC2) HPV DNA test detects approximately
20% more high-grade CIN or cancer compared to cytology
at the atypical squamous cells of undetermined signiﬁcance
(ASCUS) cut-off, but is less speciﬁc [16, 17]. Arbyn et al.
conclude that by combining HPV and cytology screening,
4% more CIN-3 lesions can be identiﬁed, although this
comes at the expense of a 7% loss in speciﬁcity, in com-
parison with only screening for HPV [17]. In the United
States, the use of combined cytology and HPV primary
screening has been approved for women older than
30 years [18]. However, in most countries, cytology-based
screening still remains the standard screening method.
Numerous studies have examined the cost-effectiveness
of cervical cancer screening with HPV DNA testing as
compared to Pap. A study by Goldhaber-Fiebert et al. used
an empirical model of the natural history of cervical cancer
to assess the quality-adjusted life years (QALYs), lifetime
costs, and incremental cost-effectiveness ratios of HPV
DNA testing compared to cytology screening with the Pap
test. The authors conclude that age-based screening with
HPV DNA testing as a triage test for equivocal results in
younger women, and as a primary screening test in older
women, is expected to be more cost-effective than current
screening practices in the United States [19]. Another study
by Kim et al. assessed the cost-effectiveness of incorpo-
rating HPV DNA testing into existing cervical cancer
screening programs in the United Kingdom, The Nether-
lands, France, and Italy. They found that HPV DNA testing
strategies were more effective than each country’s existing
screening policy and concluded that HPV DNA testing has
the potential to improve health beneﬁts at a reasonable cost
compared with current screening policies in these Euro-
pean countries [20].
Several recent studies recommend that based on the
strong evidence concerning cervical cancer prevention
technologies, including the expected impact of vaccina-
tion on the performance of cytology, a reformulation of
cervical cancer screening policies should be based on
HPV testing using validated methods followed by cyto-
logic triage [21–23]. These studies provide important
information about the cost-effectiveness of HPV testing
for cervical cancer screening. However, the results of
most of these studies are based on cost and effectiveness
parameters that were estimated using previously published
data from many different sources and are not necessarily
speciﬁc to Mexico.
We conducted an economic evaluation of HPV testing
that is based on the actual cost and effectiveness data
obtained from the cervical cancer screening program at the
Mexican Institute of Social Security (IMSS) in Morelos,
Mexico. IMSS is one of the key institutions in the Mexican
health system, which provides health care services to
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123approximately 43% of the population [24]. The coverage of
the IMSS cervical cancer screening program is estimated to
be 50%. The purpose of this cost-effectiveness analysis
(CEA) is to determine the incremental costs and effects of
using HPV testing as a screening technique for the detec-
tion of cervical cancer, in Mexico. We hope that the results
of this study will provide useful evidence to policy-makers
who will decide whether to incorporate the use of HPV
testing as part of the IMSS cervical cancer screening
program.
Materials and methods
Study design and population
This CEA used data obtained from the initial enrollment
phase of the Morelos HPV Study. The speciﬁcs regarding
the study design, methodology and baseline characteristics
of participants have been detailed elsewhere [25], and the
ethical committees of all participating institutions approved
the study protocol and consent forms for this study. The
Morelos HPV Study was conducted to examine the
potential use of HPV testing for cervical cancer screening
in Mexico. The costs and health outcomes of the following
interventions were evaluated and compared: (1) not con-
ducting cervical cancer screening, (2) using only the Pap
test, (3) using only self-HPV testing, (4) using only clini-
cian-HPV testing, and (5) using the clinician-HPV test in
conjunction with the Pap test. These ﬁve different strate-
gies were evaluated in the context of screening for two
different age groups, women aged 20–80 and 30–80. For
this analysis, the costs associated with using a clinic-based
self-HPV test, the clinician-HPV test, and the Pap test were
identiﬁed and quantiﬁed. All costs are presented in 2008
US dollars. The health outcome is the number of histo-
logically conﬁrmed cases of CIN 2/3 or cervical cancer
detected.
This CEA was performed from the perspective of the
health sector. The time horizon for this CEA is 1 year,
during which all the screening and follow-up activities
occur at the IMSS medical facilities. The target population
for this CEA is female IMSS clients, between the ages of
20–80, in the state of Morelos. This CEA was designed to
capture the most signiﬁcant effects that the different cer-
vical cancer screening interventions would have on the
target population.
Identiﬁcation and calculation of costs
Costs were estimated using micro-costing techniques,
which consist of measuring and appraising every resource
required to produce a service or ﬁnal good [26]. The IMSS
direct medical costs associated with both types of HPV
testing and Pap testing were determined individually for
each screening method [27, 28]. The IMSS direct medical
costs for the Pap, self-, and clinician-HPV tests were cal-
culated taking into account: (1) screening costs, including
the cost of sample collection, reagents and laboratory staff;
(2) costs of follow-up care for all positive results such as
colposcopy costs, which include the cost of performing a
colposcopy exam and taking a biopsy if necessary, the
laboratory costs of determining a biopsy-conﬁrmed diag-
nosis, and in the case of true positives, the cost to treat a
case of CIN 2/3 or cervical cancer; and (3) costs of false
negatives.
Each of these costs includes the product of price times
the quantity of material and human resources that were
used to complete each process. A time and motion
(TAM) study was carried out at IMSS and at the
National Institute of Public Health of Mexico (INSP) to
identify the time, quantity, labor, and equipment costs
associated with each of these processes. A list of all the
personnel involved in collecting Pap specimens was
obtained as part of the TAM study that was conducted.
These workers were observed to determine their job
responsibilities and productivity. The direct medical costs
were determined by multiplying the price (or unit cost)
by the quantity used; the price and quantity used for each
process were also reported separately. A discount rate of
3% (over the useful life of the equipment) was used
to calculate the equivalent annual cost of equipment
expenditures.
Staff costs were calculated by multiplying the amount of
time spent on each task by each worker, by the hourly rate
that each employee is paid to perform the task. The rates of
pay were obtained from the Morelos IMSS personnel ofﬁce
and the INSP personnel ofﬁce. Supply costs were deter-
mined by multiplying the units or amounts of goods con-
sumed, by the price that was paid to purchase the good.
These prices were obtained from the IMSS purchasing
catalog, the INSP HPV lab purchasing orders, and market
prices. Overhead and capital costs [29] were obtained from
the IMSS Ofﬁce of Construction, Conservation, and
Equipment, from the Morelos IMSS administrative ofﬁces,
and from the INSP administrative ofﬁces. A discount rate
of 3% over 50 years was used to annuitize capital
expenditures.
Future follow-up costs and beneﬁts were assumed to
occur in the same year as screening and did not need to be
discounted. A sensitivity analysis was performed using the
lower and upper bounds of the costs and outcomes. The
reference case costs and unconditional probabilities were
assigned minimums and maximums based on the observed
95% conﬁdence intervals (CIs) or a range of ± 25%
(Table 1).
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123Identiﬁcation and calculation of health outcomes
This CEA is based on the baseline screening results of the
Morelos HPV Study [30]. The number of CIN 2/3 and
cervical cancer cases that were detected using each
screening strategy was used as the measure of effectiveness
for this CEA. All cases were identiﬁed using histological
results as the gold standard. This measure of effectiveness
was chosen because it represents one of the main objectives
of the IMSS screening program, which is to detect as many
cases as possible, as early as possible, in order to avoid
progression of disease and death. Although CIN 2/3 is not
as serious as cervical cancer, most CIN 2/3 cases are at
greater risk of progressing to cancer if they are undetected
[31], which is why we evaluated both outcomes together.
The sensitivity and speciﬁcity results from the Morelos
HPV Study [30] that were used for this study (Table 1) are
comparable to the ﬁndings of two recent meta-analyses that
examined the diagnostic accuracy of HPV and Pap testing
for primary cervical cancer screening [16, 17].
Cost-effectiveness evaluation
A decision tree model was used to estimate the cost-
effectiveness of the various screening strategies (Fig. 1).
Decision tree models are used to represent the sequence of
chance events and decisions that occur during a speciﬁc
period of time. The probabilities assigned to each chance
Table 1 Parameters values
of the model
HVP: human papillomavirus;
CIN: cervical intraepithelial
neoplasia
a Sensitivity and speciﬁcity
estimates and 95% CIs from
Salmeron (2002)
b Yvonne Flores, unpublished
data
c Ruth Pe ´rez, unpublished data
d Insinga [33]
Parameter Base case Estimate Range
Min Max
Test performance (Sensitivity)
a
Women 20–80
Cervical cytology (Pap test) 59.4 49.2 68.9
Self-HPV test 71.3 61.3 79.6
Clinician HPV test 93.1 85.8 96.9
Clinician HPV test ? Pap test 98.0 92.3 99.7
Women 30–80
Cervical cytology (Pap test) 62.9 52.0 72.7
Self-HPV test 68.5 57.7 77.8
Clinician HPV test 92.1 83.9 96.5
Clinician HPV test ? Pap test 97.8 91.4 99.6
Test performance (Speciﬁcity)
a
Women 20–80
Cervical cytology (Pap test) 98.3 98.0 98.6
Self-HPV test 89.2 88.5 89.9
Clinician HPV test 91.8 91.2 92.4
Clinician HPV test ? Pap test 91.1 90.5 91.8
Women 30–80
Cervical cytology (Pap test) 98.2 97.8 98.5
Self-HPV test 89.6 88.8 90.3
Clinician HPV test 92.2 91.5 92.9
Clinician HPV test ? Pap test 91.4 90.7 92.1
Screening and treatment costs (in 2008 USD)
Self-HPV testing cost results 14.15 10.61 17.69
b
Clinician-HPV testing cost results 20.06 15.05 25.08
b
Clinician-HPV testing ? Pap testing cost results 26.18 19.64 32.73
b
Pap testing cost results 13.20 9.90 16.50
c
Total cost colposcopy without a biopsy 37.41 28.06 46.76
c
Total cost colposcopy with a biopsy 64.86 48.65 81.08
c
Total cost pathology 24.69 18.52 30.86
c
Average cost CIN 2/3 treatment 1,610 1,207 2,012
d
Average cost cervical cancer treatment 8,421 7,806 8,637
d
Prevalence CIN 2/3/cervical cancer 0.013 0.0098 0.0163
a
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123Sensitivity no screening
False negative
Prevalence HSIL/CC
Specificity no screening
False positive
No screening
Biopsy
No biopsy
Colposcopy
Lost to F/U
Sensitivity Pap and C-HPV
False negative
Prevalence HSIL/CC
Specificity of Pap and C-HPV
Biopsy
No biopsy
Unsatisfactory
Colposcopy
Lost to F/U
False positive 
Pap and
C-HPV test
Biopsy
No biopsy
Colposcopy
Lost to F/U
Sensitivity of Self-HPV
False negative 
Prevalence HSIL/CC
Specificity of Self-HPV 
Biopsy
No biopsy
Unsatisfactory
Colposcopy
Lost to F/U
False positive 
Self-HPV test
Biopsy
No biopsy
Colposcopy
Lost to F/U
Sensitivity of Clinician HPV (TP)
False negative
Prevalence HSIL/CC
Specificity of Clinician HPV
Biopsy
No biopsy
Unsatisfactory
Colposcopy
Lost to F/U
False positive (FP)
Clinician-
HPV test
Biopsy
No biopsy
Colposcopy
Lost to F/U
Sensitivity of Pap Test (TP)
False negative 
Prevalence HSIL/CC
Specificity of Pap Test (TN)
Biopsy
No biopsy
Unsatisfactory
Colposcopy
Lost to F/U
False positive 
Pap test
What is the most 
cost-effective CC
 screening strategy?
Fig. 1 Screening strategy
decision tree
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123occurrence are often estimated using data from clinical
studies [32]. Each branch of the decision tree represents
one of the possible sequences of chance and decision
events that could occur, which is in turn associated with a
speciﬁc consequence that is valued based on its desirabil-
ity. For this study, ﬁve cervical cancer screening strategies
(decision tree branches) were evaluated by calculating their
incremental cost-effectiveness ratios (ICERs) [32].
Although the speciﬁc probability of disease was the
same for all ﬁve screening strategies; each strategy was
assigned a speciﬁc sensitivity and speciﬁcity. Each indi-
vidual or combined screening strategy also was assigned a
series of costs that are associated with the speciﬁc number
of CIN 2/3 and CC cases that were detected. The costs
associated with each end point were assigned various codes
(e.g. the cost of both a Pap test and HPV test, the cost of a
colposcopy, the cost of a colposcopy with a biopsy, etc.),
and the probabilities of each outcome (CIN 2/3 and CC
detected vs. no CIN 2/3 or CC detected) were also coded.
The speciﬁc probabilities associated with each event were
determined from the baseline results obtained from the
Morelos HPV Study.
Our model assumes non-informative censoring of
women who were lost to follow-up, i.e. that attrition was
random with respect to health outcomes and costs. We
estimated the average cost to treat a case of CIN 2/3 atIMSS
in Morelos to be $1,610 dollars (with a range of $1,207–
$2,012 U.S.D.), and the estimated average cost to treat a
case of cervical cancer to be $8,421 dollars (with a range of
$7,806–$8,637 U.S.D.), these treatment costs were obtained
from previously published estimates in Mexico [33]. The
size of the hypothetical cohort was set at 10,000 women
aged 20–80, with 6,680 women in the hypothetical cohort
aged 30–80. These 6,680 women represent the proportion of
women from the 10,000 women cohort who would be
between the ages of 30–80 and 3,320 between 20 and
29 years of age. These numbers were estimated using the
national population totals from the Mexican 2000 Census.
The cost-effectiveness ratio (CER) of the different
screening strategies were plotted to determine which
strategies were dominated (not cost-effective as compared
to other more cost-effective options). The incremental cost-
effectiveness ratios (ICERs) of the various screening
strategy options were compared to determine the most cost-
effective, undominated screening options. The ICER, for
comparing alternatives to each other, is the difference in
their cost divided by the difference in their effectiveness, or
DCost/DEffectiveness.
Although it was hypothesized that the Pap test on its
own would be dominated by the other screening strategies,
it was important to compare each of the screening alter-
natives to the existing technology that is used to detect
cervical cancer and will continue to be used at IMSS, as
well as to the option of a no screening strategy. The cost-
effectiveness analysis was performed using Microsoft
Excel (Microsoft Windows XP) and @Risk 5.0 (Palisade
corporation 2009). All costs are reported in 2008 U.S.D.
A sensitivity analysis was performed to investigate how
the predicted cost per case prevented would change when
modifying the parameters. The following variables were
considered for the sensitivity analysis: sensitivity of the
screening tests, cost of screening tests, and treatment costs.
The results of a recently published paper that reports the
sensitivity and speciﬁcity of the Pap and HPV tests in a
sample of 50,000 women who use IMSS services in
Mexico were used to calibrate the model [34].
Results
Direct medical costs
Our results indicate that the total cost of the self-HPV test
is $14.15 U.S.D.; the total cost of the clinician-HPV test is
$20.06 U.S.D.; the total cost of performing both a clini-
cian-HPV test and a Pap is $26.18 U.S.D.; and the total
cost of a Pap test is $13.20 U.S.D. The total cost to perform
a colposcopy exam without taking a biopsy specimen is
$37.41 U.S.D.; the total cost to perform a colposcopy exam
that includes a biopsy specimen is $64.86 U.S.D.; and the
total cost to evaluate the biopsy and make a histological
diagnosis is $24.69 U.S.D.
Identiﬁcation of health outcomes
The results of the Morelos HPV Study indicate that when
women aged 20 to 80 years are screened to detect CIN 2/3
and cervical cancer, the sensitivity of the Pap test is 59.4
(95% CI 49.2–68.9) and its speciﬁcity is 98.3 (95% CI
98.0–98.6) [30]. The sensitivity of the self-HPV test is 71.3
(95% CI 61.3–79.6) and its speciﬁcity is 89.2 (95% CI
88.5–89.9), and the sensitivity of the clinician-HPV test is
93.1 (95% CI 85.8–96.9) and its speciﬁcity is 91.8 (95% CI
91.2–92.4). When used to screen women between the ages
of 20–80, the sensitivity of the Pap and clinician-HPV test
combination is 98.0 (95% CI 92.3–99.7) and its speciﬁcity
is 91.1 (95% CI 90.5–91.8) [30].
The total program costs associated with each of the
screening strategies was determined based on the cost of
the true-positive, false-positive, true-negative, and false-
negative cases that were identiﬁed. Table 2 shows a
breakdown of the costs associated with each screening
strategy based on diagnostic performance when used to
screen women between the ages of 20–80 and women aged
30–80. Although the cost to perform a Pap test at IMSS is
$13.20 U.S.D., the average cost to screen one woman aged
266 Cancer Causes Control (2011) 22:261–272
12320–80 using the Pap test at IMSS is actually $72.19 U.S.D.
when one takes into account the cost of false negatives,
false positives, true positives, and true negatives, in addi-
tion to the cost of the screening test. Likewise, while the
cost of a self-HPV screening test is $14.15 U.S.D., the
average cost to screen one woman aged 20–80 using the
self-HPV test is $67.17. The cost of the clinician-HPV
screening test is $20 U.S.D., and the average cost to screen
one woman aged 20–80 using the clinician-HPV test is
estimated at $52.46. The Pap and clinician-HPV screening
test combination is $26.18 U.S.D., while the average cost
to screen one woman aged 20–80 using the Pap and cli-
nician-HPV test combination is $54.92 (Table 2).
Reference case cost-effectiveness analysis
Five different cervical cancer screening strategies were
compared to determine the most cost-effective option(s) in
two age groups of women (20–80 and 30–80). Table 3 pre-
sents the incremental cost-effectiveness results of ten differ-
ent cervical cancer screening interventions from the
perspectiveofIMSS.Thefollowingscreeningstrategieswere
found to be viable: (1) Pap and clinician-HPV testing of
women aged 30–80, (2) Clinician-HPV testing for women
30–80,and(3)Papandclinician-HPV testingofwomenaged
20–80. The three dominated strategies in both age groups
wereself-administeredHPVtesting,Paptestingalone,andno
screening.Figure 2providesa graphical representationofthe
incremental cost-effectiveness of these screening strategies.
Additionally, when the model was calibrated by using a
Pap test sensitivity of 40%, as recently reported by Lazcano
et al. [34], we found that the cost-effectiveness ratio
increased from a base case result of $9,352 to $17,060 USD
for women 20–80, and from $8,416 to $16,159 USD for
women 30–80 (Data not shown).
Sensitivity analysis
Table 4 presents the results of the one-way sensitivity
analysis that was performed. Of the parameters that were
explored, the sensitivity of the screening tests had the
greatest effect on the cost-effectiveness results. The cost-
effectiveness ratios varied by as much as 38 and 37%,
respectively, when a low sensitivity was used for both the
Table 2 Total cost of screening women aged 20–80 and 30–80 for each strategy
No Screening Pap Self-HPV C-HPV Pap and C-HPV
Women 20–80 (n = 10,000)
True positives 0 78 93 122 128
True negatives 0 9,701 8,803 9,060 8,991
False positives 0 168 1,066 809 878
False negatives 131 53 38 9 3
Cost of screening test $0.00 $13.20 $14.15 $20.06 $26.18
Cost of true positives $0.00 $133,594.50 $159,374.10 $209,792.42 $220,893.44
Cost of true negatives $0.00 $128,053.20 $124,562.45 $181,743.60 $235,384.38
Cost of false positives $0.00 $13,206.30 $67,188.02 $57,074.83 $67,587.82
Cost of false negatives $1,103,151.00 $447,012.60 $320,535.70 $75,969.54 $25,341.54
Total program cost $1,103,151.00 $721,866.60 $671,660.27 $524,580.39 $549,207.18
Total cost per woman $110.32 $72.19 $67.17 $52.46 $54.92
Women 30–80 (n = 6,680)
True positives 0 82 90 121 128
True negatives 0 6,431 5,868 6,038 5,986
False positives 0 118 681 511 563
False negatives 131 49 41 10 3
Cost of screening test $0.00 $13.20 $14.15 $20.06 $26.18
Cost of true positives $0.00 $140,445.50 $154,233.00 $208,072.81 $220,893.44
Cost of true negatives $0.00 $84,889.20 $83,032.20 $121,122.28 $156,713.48
Cost of false positives $0.00 $9,164.91 $42,757.29 $36,074.75 $43,415.47
Cost of false negatives $1,103,151.00 $413,275.80 $345,841.15 $84,410.60 $25,341.54
Total program cost $1,103,151.00 $647,775.41 $625,863.64 $449,680.44 $446,363.93
Total cost per woman $165.14 $96.97 $93.69 $67.32 $66.82
HPV: human papillomavirus, C-HPV: Clinician HPV test
Costs reported in 2008 US dollars
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123Table 3 Incremental cost-effectiveness of ten cervical cancer screening strategies
Screening strategy (A) Program
costs
(B) Cost of
missed CC cases
(C) Total
cost
(D)
Incremental
cost
(E) Total
cases
detected
(F)
Incremental
cases detected
(G) Incremental
Cost/
Effectivenes
Ratio (ICER)
Pap and Clinician-HPV test
(30–80 y)
$421,022 $25,342 $446,364 – 128 –
Clinician-HPV test (30–80 y) $365,270 $84,411 $449,681 $3,317 121 – Dominated
a
Clinician-HPV test (20–80 y) $448,611 $75,970 $524,581 $78,217 122 – Dominated
a
Pap and clinician-HPV test
(20–80 y)
$523,865 $25,342 $549,207 $102,843 128 – Dominated
a
Self-HPV test (30–80 y) $280,023 $345,841 $625,864 $179,500 90 – Dominated
a
Pap test (30–80 y) $234,499 $413,276 $647,775 $201,411 82 – Dominated
a
Self-HPV test (20–80 y) $351,125 $320,536 $671,661 $225,297 93 – Dominated
a
Pap test (20–80 y) $274,854 $447,013 $721,867 $275,503 78 – Dominated
a
No screening (20–80 y) $0 $1,103,151 $1,103,151 $656,787 0 – Dominated
a
No screening (30–80 y) $0 $1,103,151 $1,103,151 $653,470 0 – Dominated
a
Assessed for base-case: prevalence of CIN 2/3 and cervical cancer (CC) was 1.3%. All costs are in 2008 US dollars
(A) Program costs include ﬁxed and variable costs associated with the cost of baseline screening test and follow-up conﬁrmatory tests such as
colposcopy and histology
(B) The estimated cost of subsequent treatment for an undetected case of CC is $8,421 US dollars; the cost of lost CC cases = Number of
undetected CC cases (131 - (D)) 9 $8,421
(C) Total program costs = Program costs (A) ? Cost of missed CC cases (false negatives) (B). (See Table 1)
(D) The incremental cost is the difference in cost between each strategy and the next best undominated strategy
(E) Number of CIN 2/3 and CC cases detected by the speciﬁed screening strategy
(F) The difference in the number of cases detected by each of the three undominated screening strategies
(G) Incremental cost/effectiveness ratio = Incremental cost/incremental CIN 2/3 and CC cases detected
a A dominated strategy costs more and is less effective than the undominated strategies
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Fig. 2 Cost-effectiveness of 10 cervical cancer screening strategies*
* Note: The points along the lines represent non-dominated strategies that are cost-effective. The points below the lines represent dominated
strategies that are not cost-effective
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123Pap and self-HPV tests. Varying the cost of the screening
test had a greater effect on the cost-effectiveness ratios of
the clinician-HPV test and the Pap and clinician-HPV test
combination. Varying the costs of treatment also had a
slightly greater effect on the cost-effectiveness ratios of the
clinician-HPV test and the Pap and clinician-HPV test
combination.
Discussion
The results of this CEA indicate that screening women
between the ages of 30–80 for cervical cancer using clin-
ical-HPV testing or the combination of clinical-HPV test-
ing and the Pap is always more cost-effective than using
the Pap test alone. HPV testing for women aged 30–80 was
found to be more cost-effective than screening women
between the ages of 20–80. The total cost to perform a
clinician-HPV test ($20 U.S.D.) and the clinician-HPV and
Pap test combination ($26.18 U.S.D.) are higher than the
cost of the self-HPV test ($14.15 U.S.D.) and the Pap test
($13.20 U.S.D.). But when one reckons the cost of false
negatives, false positives, true positives, and true negatives,
in addition to the cost of the screening test, the total costs
associated with the self-administered HPV test and the Pap
test exceed those of tests with fewer false negatives. When
one considers the costs of missed cases, the clinician-HPV
test emerges as the least expensive option ($52.46 U.S.D.
per case detected), because it is able to detect 93% of all
cervical cancer cases. The use of the Pap and clinician-
HPV test combination is the next least expensive screening
option ($54.92 U.S.D. per case detected) with the ability to
identify 98% of cervical cancer cases, which represents
64% more cases than the Pap test on its own.
There are certain factors that should be considered when
deciding which HPV screening strategy is the most appro-
priate, based on the results of this CEA. If an organization
such as IMSS is already spending more money on Pap
testing than it would using HPV testing, it might be better to
implement a more cost-effective cervical cancer screening
strategy such as clinician-HPV testing. Our results indicate
that clinician-HPV testing is signiﬁcantly more effective at
detecting CIN 2/3 and cervical cancer cases and is less
expensive than the Pap test, when one considers the average
costs incurred by the tests. The Pap and clinician-HPV test
combination could also be taken into account, since it is
only slightly more expensive than clinician-HPV testing,
and is able to detect a greater number of CIN 2/3 and cer-
vical cancer cases than either the Pap or clinician-HPV test
on its own.
Deciding which HPV testing strategy is the most appro-
priate depends not only on the cost and effectiveness of each
option, but on the speciﬁc needs and circumstances of the
organizations or communities that will be affected by the
implementationofHPVtesting.Indevelopingcountriesthat
have little or no cervical cancer screening infrastructure, the
Table 4 One-way sensitivity analysis results
Test Varying sensitivity of tests Varying costs of tests Varying costs of treatment
(CIN2/3 and CC)
Base case Low estimate High estimate Low estimate High estimate Low estimate High estimate
Pap 20–80 9,277 12,613
?36%
7,085
-24%
8,827
-5%
9,775
?5%
8,470
-9%
9,843
?6%
Pap 30–80 7,861 10,879
?38%
5,868
-25%
7,516
-4%
8,142
?4%
7,063
-10%
8,358
?6%
Self-HPV 20–80 7,191 9,427
?31%
5,714
-21%
6,621
-8%
7,703
?7%
6,511
-9%
7,651
?6%
Self-HPV 30–80 6,975 9,562
?37%
5,355
-23%
6,616
-5%
7,373
?6%
6,309
-10%
7,496
?7%
Clin-HPV 20–80 4,301 5,241
?22%
3,871
-10%
3,786
-12%
4,821
?12%
3,855
-10%
4,721
?10%
Clin-HPV 30–80 3,727 4,770
?28%
3,269
-12%
3,393
-9%
4,100
?10%
3,291
-12%
4,167
?12%
Pap & Clin-HPV 20-80 4,278 4,938
?15%
4,071
-5%
3,640
-15%
4,878
?14%
3,843
-10%
4,278
?9%
Pap & Clin-HPV 30-80 3,484 4,192
?20%
3,293
-5%
3,059
-12%
3,898
?12%
3,061
-12%
3,885
?12%
Cost-effectiveness ratios (cost per case prevented of CIN2/3 or cancer)
In US dollars of 2008 year. (Base case scenario is the total costs divided by cases detected)
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123self-HPV testing strategy may be more appropriate [35, 36].
Self-HPV testing can be performed in a non-clinical setting,
without the participation of medical personnel. Women can
collect their own vaginal specimens basically anywhere,
includinginthecomfortoftheirownhomes,usinganeasyto
use self-HPV test collection kit. The laboratory facilities
required to perform the HPV testing are inexpensive, simple
to mount, take up little space, and can be staffed by per-
sonnel that can be trained in just a few weeks [37]. Since
HPVtestingproceduresaresemi-automated,thereisalower
probability of human error than with Pap testing.
However, the use of self-HPV testing may not be an
appropriate option for countries such as Mexico that have a
well-established, though not necessarily effective, national
cervical cancer screening program. Implementing a com-
pletely different screening program that disregards the
existing cervical cancer screening resources and infra-
structure might not be an effective or feasible alternative. A
more appropriate course of action would be to incorporate
a screening strategy that makes use of the existing clinical
resources and infrastructure to improve the quality and
effectiveness of the cervical cancer screening program.
Implementing the use of the clinician-HPV test, or the
Pap and clinician-HPV test combination, would greatly
improve the case detection capabilities of the IMSS cer-
vical cancer screening program in Mexico, at little or no
additional cost. However, even in Mexico, self-HPV test-
ing could be considered the more appropriate and accept-
able cervical cancer screening option for women who have
a difﬁcult time getting to and from a clinic setting, or who
refuse to undergo a pelvic exam [38].
A recent study by Goldie et al. used empirically cali-
brated models to assess the cost-effectiveness of HPV
vaccination for 33 countries in Latin America and the
Caribbean, including Mexico [39]. Although this study
focused on the use of HPV vaccination to prevent cervical
cancer, the authors also assessed screening with cytology
3 times per lifetime at 70% coverage, HPV vaccination,
and HPV vaccination plus screening with HPV DNA
testing 3 times per lifetime at 70% coverage, and con-
cluded that HPV DNA testing was the most effective and
cost-effective of the screening strategies [39]. Another
study investigated the cost-effectiveness of different cer-
vical cancer prevention strategies in Mexico [40]. The
results of this study, which uses data obtained from the
Ministry of Health (MoH) of Mexico, also indicate that the
combined use of the Pap and HPV test is a cost-effective
screening option [40].
One of the strengths of this CEA is that it uses the results
of a population-based screening program that was speciﬁ-
cally designed to evaluate the use of HPV testing to detect
cervical cancer. This is the ﬁrst CEA that compares the use
of HPV testing to the Pap test in Mexico, using program
costs and effectiveness parameters that were obtained from
the IMSS cervical cancer screening program. The goal of
this CEA is inform decision makers at IMSS about the
potentialbeneﬁtsofincorporatingtheHPVtestaspartofthe
national cervical cancer screening program.
Alimitationofthisstudyistheassumptionthatthecostof
a missed case of cervical cancer is $8,421 U.S.D., and the
cost to treat a case of CIN 2/3 is $1,610 U.S.D. These esti-
mates are not based on direct measurements from the IMSS
cervical cancer screening program in Morelos. Additional
research should be conducted to determine the actual cost of
amissedcaseofCIN2/3orcervicalcanceratIMSS,because
having more speciﬁc information would improve the CEA
results. These CEA results are also limited in that they are
cross-sectional. This analysis examines the cost-effective-
ness of different cervical cancer options at one point in time.
A CEA that evaluates the performance of HPV testing when
compared to the Pap over the course of several years could
provide additional data about the long-term cost-effective-
ness of HPV testing in Mexico.
The results of this analysis suggest that the Pap test is
not the most appropriate or cost-effective cervical cancer
screening option for the IMSS cervical cancer screening
program in Mexico. The ﬁndings of this CEA indicate that
the Pap is less accurate and effective, in addition to being a
more expensive screening option. The cost of the Pap test
itself is not necessarily high, but the cost of the false
negatives is signiﬁcant. This CEA suggests that HPV
testing could be a more cost-effective and appropriate
cervical cancer screening alternative for a large, national
health delivery organization such as IMSS. This ﬁnding is
especially relevant now that the HPV vaccine is available
in Mexico. The HPV vaccine is currently being offered to
girls between the ages of 11 and 13 years at IMSS and the
Secretarı ´a de Salud (Mexican MoH). The presence of an
HPV vaccination program in Mexico is bound to change
cervical cancer screening policies, with a move toward
HPV screening in the near future. A cervical cancer
screening program that includes HPV testing in the context
of an HPV vaccination program is likely to be even more
cost-effective and could also be used for the epidemiologic
surveillance of the vaccine program.
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